February 18, 2021

Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): immunity, vaccines, variants

Neutralizing activity of sera from recipients of the 2-dose Pfizer vaccine (n=15, 20 serum samples) against wild-type SARS-CoV-2 (USA-WA1/2020) engineered with the full set of spike protein mutations of the B.1.351 variant was weaker than the USA-WA1/2020 strain by approximately two-thirds. Using 50% plaque reduction neutralization testing (PRNT50) on sera obtained 2-4 weeks after the second dose, geometric mean titers against USA-WA1/2020, USA-WA1/2020 with the globally dominant D614G mutation, USA-WA1/2020 with key B.1.351 mutations (K417N, E484K, and N501Y), and USA-WA1/2020 with the full set of B.1.351 mutations were 501, 485, 331, and 184, respectively.

Liu et al. (Feb 17, 2021). Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report. New England Journal of Medicine. https://doi.org/10.1056/NEJMc2102017